Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Calabresi, Peter A [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport - Fang, Jun ELSEVIER, 2014transfer abstract, London |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2014 ; number:7 ; pages:657-665 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1474-4422(14)70068-7 |
|---|
| Katalog-ID: |
ELV027902072 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV027902072 | ||
| 003 | DE-627 | ||
| 005 | 20230623191751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(14)70068-7 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014004000028.pica |
| 035 | |a (DE-627)ELV027902072 | ||
| 035 | |a (ELSEVIER)S1474-4422(14)70068-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.17 |2 bkl | ||
| 084 | |a 58.50 |2 bkl | ||
| 084 | |a 43.12 |2 bkl | ||
| 100 | 1 | |a Calabresi, Peter A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| 264 | 1 | |c 2014 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. | ||
| 700 | 1 | |a Kieseier, Bernd C |4 oth | |
| 700 | 1 | |a Arnold, Douglas L |4 oth | |
| 700 | 1 | |a Balcer, Laura J |4 oth | |
| 700 | 1 | |a Boyko, Alexey |4 oth | |
| 700 | 1 | |a Pelletier, Jean |4 oth | |
| 700 | 1 | |a Liu, Shifang |4 oth | |
| 700 | 1 | |a Zhu, Ying |4 oth | |
| 700 | 1 | |a Seddighzadeh, Ali |4 oth | |
| 700 | 1 | |a Hung, Serena |4 oth | |
| 700 | 1 | |a Deykin, Aaron |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Lancet Publ. Group |a Fang, Jun ELSEVIER |t Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |d 2014transfer abstract |g London |w (DE-627)ELV017537959 |
| 773 | 1 | 8 | |g volume:13 |g year:2014 |g number:7 |g pages:657-665 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1474-4422(14)70068-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 35.17 |j Katalyse |q VZ |
| 936 | b | k | |a 58.50 |j Umwelttechnik: Allgemeines |q VZ |
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2014 |e 7 |h 657-665 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
p a c pa pac |
|---|---|
| matchkey_str |
calabresipeterakieseierberndcarnolddougl:2014----:eyaeitreobt1freasnrmtigutpeceoiavnern |
| hierarchy_sort_str |
2014 |
| bklnumber |
35.17 58.50 43.12 |
| publishDate |
2014 |
| allfields |
10.1016/S1474-4422(14)70068-7 doi GBVA2014004000028.pica (DE-627)ELV027902072 (ELSEVIER)S1474-4422(14)70068-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Kieseier, Bernd C oth Arnold, Douglas L oth Balcer, Laura J oth Boyko, Alexey oth Pelletier, Jean oth Liu, Shifang oth Zhu, Ying oth Seddighzadeh, Ali oth Hung, Serena oth Deykin, Aaron oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:7 pages:657-665 extent:9 https://doi.org/10.1016/S1474-4422(14)70068-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 7 657-665 9 045F 610 |
| spelling |
10.1016/S1474-4422(14)70068-7 doi GBVA2014004000028.pica (DE-627)ELV027902072 (ELSEVIER)S1474-4422(14)70068-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Kieseier, Bernd C oth Arnold, Douglas L oth Balcer, Laura J oth Boyko, Alexey oth Pelletier, Jean oth Liu, Shifang oth Zhu, Ying oth Seddighzadeh, Ali oth Hung, Serena oth Deykin, Aaron oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:7 pages:657-665 extent:9 https://doi.org/10.1016/S1474-4422(14)70068-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 7 657-665 9 045F 610 |
| allfields_unstemmed |
10.1016/S1474-4422(14)70068-7 doi GBVA2014004000028.pica (DE-627)ELV027902072 (ELSEVIER)S1474-4422(14)70068-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Kieseier, Bernd C oth Arnold, Douglas L oth Balcer, Laura J oth Boyko, Alexey oth Pelletier, Jean oth Liu, Shifang oth Zhu, Ying oth Seddighzadeh, Ali oth Hung, Serena oth Deykin, Aaron oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:7 pages:657-665 extent:9 https://doi.org/10.1016/S1474-4422(14)70068-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 7 657-665 9 045F 610 |
| allfieldsGer |
10.1016/S1474-4422(14)70068-7 doi GBVA2014004000028.pica (DE-627)ELV027902072 (ELSEVIER)S1474-4422(14)70068-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Kieseier, Bernd C oth Arnold, Douglas L oth Balcer, Laura J oth Boyko, Alexey oth Pelletier, Jean oth Liu, Shifang oth Zhu, Ying oth Seddighzadeh, Ali oth Hung, Serena oth Deykin, Aaron oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:7 pages:657-665 extent:9 https://doi.org/10.1016/S1474-4422(14)70068-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 7 657-665 9 045F 610 |
| allfieldsSound |
10.1016/S1474-4422(14)70068-7 doi GBVA2014004000028.pica (DE-627)ELV027902072 (ELSEVIER)S1474-4422(14)70068-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Kieseier, Bernd C oth Arnold, Douglas L oth Balcer, Laura J oth Boyko, Alexey oth Pelletier, Jean oth Liu, Shifang oth Zhu, Ying oth Seddighzadeh, Ali oth Hung, Serena oth Deykin, Aaron oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:7 pages:657-665 extent:9 https://doi.org/10.1016/S1474-4422(14)70068-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 7 657-665 9 045F 610 |
| language |
English |
| source |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:13 year:2014 number:7 pages:657-665 extent:9 |
| sourceStr |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:13 year:2014 number:7 pages:657-665 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Katalyse Umwelttechnik: Allgemeines Umweltchemie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| authorswithroles_txt_mv |
Calabresi, Peter A @@aut@@ Kieseier, Bernd C @@oth@@ Arnold, Douglas L @@oth@@ Balcer, Laura J @@oth@@ Boyko, Alexey @@oth@@ Pelletier, Jean @@oth@@ Liu, Shifang @@oth@@ Zhu, Ying @@oth@@ Seddighzadeh, Ali @@oth@@ Hung, Serena @@oth@@ Deykin, Aaron @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV017537959 |
| dewey-sort |
3610 |
| id |
ELV027902072 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027902072</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623191751.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(14)70068-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027902072</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(14)70068-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Calabresi, Peter A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kieseier, Bernd C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, Douglas L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balcer, Laura J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boyko, Alexey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pelletier, Jean</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Shifang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seddighzadeh, Ali</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hung, Serena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deykin, Aaron</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:657-665</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(14)70068-7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2014</subfield><subfield code="e">7</subfield><subfield code="h">657-665</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Calabresi, Peter A |
| spellingShingle |
Calabresi, Peter A ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| authorStr |
Calabresi, Peter A |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV017537959 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| topic |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_unstemmed |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_browse |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b c k bc bck d l a dl dla l j b lj ljb a b ab j p jp s l sl y z yz a s as s h sh a d ad |
| hierarchy_parent_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| hierarchy_parent_id |
ELV017537959 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV017537959 |
| title |
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| ctrlnum |
(DE-627)ELV027902072 (ELSEVIER)S1474-4422(14)70068-7 |
| title_full |
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| author_sort |
Calabresi, Peter A |
| journal |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| journalStr |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
657 |
| author_browse |
Calabresi, Peter A |
| container_volume |
13 |
| physical |
9 |
| class |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Calabresi, Peter A |
| doi_str_mv |
10.1016/S1474-4422(14)70068-7 |
| dewey-full |
610 570 540 |
| title_sort |
pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (advance): a randomised, phase 3, double-blind study |
| title_auth |
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| abstract |
Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. |
| abstractGer |
Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. |
| abstract_unstemmed |
Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 |
| container_issue |
7 |
| title_short |
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study |
| url |
https://doi.org/10.1016/S1474-4422(14)70068-7 |
| remote_bool |
true |
| author2 |
Kieseier, Bernd C Arnold, Douglas L Balcer, Laura J Boyko, Alexey Pelletier, Jean Liu, Shifang Zhu, Ying Seddighzadeh, Ali Hung, Serena Deykin, Aaron |
| author2Str |
Kieseier, Bernd C Arnold, Douglas L Balcer, Laura J Boyko, Alexey Pelletier, Jean Liu, Shifang Zhu, Ying Seddighzadeh, Ali Hung, Serena Deykin, Aaron |
| ppnlink |
ELV017537959 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1474-4422(14)70068-7 |
| up_date |
2024-07-06T17:25:37.221Z |
| _version_ |
1803851385769295872 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027902072</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623191751.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(14)70068-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027902072</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(14)70068-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Calabresi, Peter A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kieseier, Bernd C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, Douglas L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balcer, Laura J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boyko, Alexey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pelletier, Jean</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Shifang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seddighzadeh, Ali</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hung, Serena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deykin, Aaron</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:657-665</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(14)70068-7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2014</subfield><subfield code="e">7</subfield><subfield code="h">657-665</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402137 |